Effects of doxorubicin combined with cisplatin on efficacy, survival rate and toxicity in cervical cancer patients with radiotherapy

Objective To analyze the effect and clinical value of doxorubicin and cisplatin in combination for chemotherapy in cervical cancer patients with radiotherapy. Methods A total of 120 patients with cervical cancer were selected, and equally divided into treatment group(receiving doxorubicin and cisplatin in combination for chemotherapy)and routine group(receiving cisplatin for chemotherapy). The biochemical indicators, treatment effects, survival rates and toxic and side effects of two groups were compared before and after treatment. Results Compared with the conventional group, the disease control rate, Ki-67 protein expression level, and local recurrence rate were significantly lower, and expression levels of fragile intracellular histamine triplet(FHIT)protein and Bcl-2 associated protein X(Bax)in the treatment group were significantly higher(P<0.05); there were no differences in the half-year survival rate, distant metastasis rate, and incidence of toxic and side effects between the two groups(P>0.05). The local recurrence rate in the treatment group was significantly lower than that in the conventional group(P<0.05). Conclusion Doxorubicin and cisplatin in combination as chemotherapy for patients with cervical cancer can significantly improve treatment effect, and has less toxic and side effects.